Non-System-Specific Biopharmaceuticals

AstraZeneca PLC

Salesforce

Conference Minutes

INFA

VEEV

TWTR

08391

4502

Below is Dolphin Research's Trans of $Salesforce(CRM.US) FY26 Q4 earnings call.For our earnings analysis, cf. 'Salesforce: The AI replacement thesis sweeps the field — has the SaaS leader been cast aside?'Key takeaways recap1) Q1 guidance: revenue of $11.03–11.08bn, implying reported growth of ~12–13%.Management also guides Q1 CRPO to grow ~14% YoY on a reported basis ...

ServiceNow

Informatica

Veeva Systems -CL

Sunrun

AstraZeneca

Pfizer

Twitter

CORNERSTONE TEC

Takeda Pharmaceutical Co. Ltd.

CRM Trans: Organic rev. growth to re-accelerate in H2 FY

---

AstraZeneca and Daiichi Sankyo's Enhertu Approved by FDA for HER2+ Early Breast Cancer

AstraZeneca's Baxfendy Approved in US, Outpacing Mineralys Therapeutics

JPMorgan and Jefferies Maintain Buy Rating on AstraZeneca, Deutsche Bank Reaffirms Sell

AstraZeneca Late-Stage Trial Shows Imfinzi and enfortumab vedotin Significantly Improve Survival Rates for Muscle-Invasive Bladder Cancer Patients

EMA Approves Baxfendy for Refractory Hypertension

AstraZeneca's ENEBOPARATIDE Meets Primary Endpoint in Phase III Trial

Dapagliflozin Generic Drugs Approved by FDA, Market Enters Full Competition Phase

AstraZeneca's Truqap and Abiraterone Combination Therapy for Prostate Cancer Receives FDA Support

AstraZeneca's Camizestrant Application for Breast Cancer Treatment Split in FDA Vote

Bernstein Downgrades AstraZeneca Target Price

Jefferies Analyst Reiterates Buy Rating on AstraZeneca

FDA Rejects AstraZeneca's Breast Cancer Drug Camizestrant

AstraZeneca's Q1 2026 Earnings Exceed Expectations but Stock Price Drops

AstraZeneca to Resume Cambridge Investment Project

AstraZeneca Plans to Invest 300 Million Pounds in UK Life Sciences

AstraZeneca Q1 Core EPS Exceeds Expectations

Paradigm Health Collaborates with FDA to Accelerate Clinical Trial Review

AstraZeneca's Breztri Aerosphere Approved by FDA for Asthma Treatment

AstraZeneca Approved by China's National Medical Products Administration for Hepatocellular Carcinoma Treatment

AstraZeneca Receives Approval for Two Drugs for Liver Cancer Treatment

Pinned News

置顶新闻

Mitie wins GBP 26 million AstraZeneca engineering services contract at Macclesfield site

Mitie has secured a GBP 26 million contract to deliver engineering and energy services at AstraZeneca’s Macclesfield campus. The contract includes mechanical and electrical maintenance, energy management, and optimization, with a focus on tracking energy use and carbon emissions. Additionally, it involves investment in apprenticeships and a commitment to over 1,300 volunteering hours annually for community projects.

PUBT

MITIE Group PLC

AstraZeneca has received US approval for Baxfendy, a first-in-class aldosterone synthase inhibitor for adults with uncontrolled hypertension. The approval follows positive phase 3 trial results showing significant reductions in systolic blood pressure. Hypertension affects 1.4 billion globally, with many patients not achieving control despite treatment. Baxfendy targets aldosterone production, offering a new option for the 23 million US patients struggling with hypertension management.

PharmaTimes

AstraZeneca wins US approval for first‑in‑class Baxfendy in hypertension

AstraZeneca received FDA approvals for Baxfendy, a hypertension treatment, and Enhertu for early HER2-positive breast cancer. Baxfendy targets uncontrolled hypertension, while Enhertu's approvals cover neoadjuvant and adjuvant settings. These milestones will result in $155 million payments to Daiichi Sankyo. AstraZeneca shares rose 1.56% to $184.42, despite a 9.1% decline over the past month.

Fidelity

Mineralys Therapeutics

Daiichi Sankyo Company, Limited

Daiichi Sankyo

S&P 500

AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology Portfolios

RYAAY

European stock markets rose on Monday, with the Stoxx Europe up 0.4% and Germany's DAX gaining 1.3%, amid rising oil prices and interest rates. In corporate news, Novartis reported positive results for its Pluvicto cancer medication, while AstraZeneca and Roche announced a partnership in digital pathology. UBS faced senior banker departures, and Ryanair warned of challenges due to high fuel prices. GSK's RSV vaccine received expanded approval in Japan.

Ryanair

NOVARTIS AG

UBS Group AG

GlaxoSmithKline plc

Novartis AG

Ryanair Holdings Plc

GSK plc Sponsored ADR

European Stocks Trend Higher in Monday Trading Despite Specter of Middle East War Reigniting

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

FDA approves Enhertu for two HER2-positive early breast cancer indications

DSNKY

4568

The FDA has expanded the use of Enhertu (trastuzumab deruxtecan) for HER2-positive Stage II and III breast cancer, approving it for neoadjuvant and adjuvant settings. The neoadjuvant approval is based on the DESTINY-Breast11 trial, showing a 67.3% pathologic complete response. The adjuvant approval, based on DESTINY-Breast05, demonstrated a 53% reduction in recurrence risk. These approvals enhance treatment options and have significant financial implications, including $155 million in milestone payments.

Pharmexec

<![CDATA[FDA Expands Enhertu in Early HER2-Positive Breast Cancer]]>

The FDA has approved AstraZeneca and Daiichi Sankyo's ENHERTU for neoadjuvant and adjuvant treatment of HER2-positive early breast cancer, based on Phase III trial results. ENHERTU is now approved for adult patients with Stage II or III breast cancer and those with residual disease post-treatment. It is already approved in over 95 countries for metastatic breast cancer.

rttnews

AZN :FDA Approves ENHERTU For HER2-Positive Early Breast Cancer In Neoadjuvant And Adjuvant Settings

NGLOY

Anglo American plans to sell its steelmaking coal assets to Dhilmar for up to $3.875 billion, completing its exit strategy. AstraZeneca received U.S. approval for its hypertension drug, Baxfendy, expected to generate over $5 billion in revenue. Activist investor Elliott has increased its stake in Bio-Rad, while Apple continues to profit from devices using lower-performing chips. Samsung is in negotiations to avoid a strike, and Tesla has raised prices on some Model Y trims by $1,000.

MorningStar

Anglo American

Peabody Energy

Bio-Rad Lab

Sartorius AG

Apple

Samsung Electronics 

Allegiant Travel

Frontier

Tesla

Walmart

Target

Nextera Energy

Dominion Energy

OpenAI

BlackRock

TCP Capital

Amgen

Kissei Pharmaceutical Co., Ltd.

Bio-Rad Lab-B

Samsung Electronics Co., Ltd. Sponsored GDR

NEXTERA ENERGY CAPITAL HLDGS INC 5.65%JNR SUBORD DEB 01/03/2079 SER N

NEXTERA ENERGY CAPITAL HLDGS INC 6.5% BDS 15/04/86 USD1000

Nextera Energy Partners LP

NEXTERA ENERGY INC 6.926% CORPORATE UNITS 01/09/2025

NEXTERA ENERGY INC CORP UNIT 01/11/2029

NEXTERA ENERGY CAPITAL HLDGS INC 6.5% BDS 01/06/85 USD25

NEXTERA ENERGY INC CORP UNIT 01/06/2027

NEXTERA ENERGY INC CORP UNIT

BlackRock Tech and Private Equity Term Trust

BLACKROCK MULTI-SECTOR INCOME TR COM USD0.001(S/R 09/09/2025) WI

Blackrock Enhanced Div Achievers Trust

BlackRock Science and Tech Term Trust

BlackRock Multi-Sector Income Trust

Dow Jones Top Company Headlines at 3 AM ET: Anglo American to Sell Steelmaking Coal Assets to Dhilmar for Up to $3.875 Billion | AstraZeneca ...

AstraZeneca PLC(AZN.UK)